Results 31 to 40 of about 4,313 (158)

Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report

open access: yesRespiratory Medicine Case Reports, 2020
Eosinophilic chronic rhinosinusitis (ECRS) is characterized by the presence of nasal polyps, dominant ethmoid shadows in computed tomography (CT) scans, and elevated levels of eosinophil infiltration into the nasal polyps and peripheral blood.
Hiroki Kagoshima   +7 more
doaj   +1 more source

Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics

open access: yesERJ Open Research, 2023
Background Benralizumab is highly effective in many, but not all, patients with severe asthma. Baseline characteristics alone are insufficient to predict an individual's probability of long-term benralizumab response.
Johannes A. Kroes   +6 more
doaj   +1 more source

Real-life study of the cost-effectiveness of benralizumab vs previous care in Bulgaria [PDF]

open access: yesPharmacia
The aim is to evaluate the cost-effectiveness of benralizumab therapy in real-life settings in Bulgaria in comparison with previous care. The point of view is that of the national health insurance fund, and the time horizon is for one year.
Konstantin Tachkov   +2 more
doaj   +3 more sources

Anaphylaxis to three humanized antibodies for severe asthma: a case study

open access: yesAllergy, Asthma & Clinical Immunology, 2020
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo   +9 more
doaj   +1 more source

Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Biologics and endoscopic sinus surgery (ESS) treat refractory chronic rhinosinusitis with nasal polyposis (CRSwNP), but direct comparisons are lacking. We synthesized efficacy and subgroup data across randomized controlled trials (RCTs) of biologics and ESS.
Arun Chakravorty   +13 more
wiley   +1 more source

Benralizumab for the Prevention of COPD Exacerbations [PDF]

open access: yesNew England Journal of Medicine, 2019
The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on ...
Criner G. J.   +221 more
openaire   +11 more sources

Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis

open access: yesRespirology Case Reports, 2023
There is limited data on the use of benralizumab in patients with severe asthma, who have allergic bronchopulmonary aspergillosis (ABPA). We report the case of a 65‐year‐old woman with combined severe eosinophilic and allergic asthma, who presented with ...
Arvindran Alaga   +2 more
doaj   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl   +14 more
wiley   +1 more source

Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Paradoxical atopic dermatitis (AD) can arise during biologic therapy for psoriasis due to an immune‐axis imbalance. We describe a 47‐year‐old man who developed severe AD while receiving secukinumab, which was successfully managed with the addition of dupilumab, allowing long‐term control of both diseases.
So Yun Park   +6 more
wiley   +1 more source

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma

open access: yesEuropean Clinical Respiratory Journal
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre ...
Kohei Somekawa   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy